FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. entered into an agreement to acquire Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) for CNY 5.8 billion on August 17, 2021. The consideration will be paid in two installments. As of May 25, 2022, the 1st tranche of purchase payment pursuant to the terms of the ôEquity Sale Agreementö totaling ANY 5,407,325,466 has been paid. For the year ended April 30, 2021, Beijing Zhendong Langdi Pharmaceutical reported total assets of CNY 450.33 million and total liabilities of CNY 169.79 million. The transaction was approved by Shanxi Zhendong Pharmaceutical board. The Zhendong PharmaceuticalÆs shareholders at the general meeting reviewed the relevant proposals for this transaction and voted in favor. The Fanglang completed the anti-monopoly review procedure.
FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. completed the aquistion of Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) on October 28, 2022.